These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Natural products used as a chemical library for protein-protein interaction targeted drug discovery. Jin X; Lee K; Kim NH; Kim HS; Yook JI; Choi J; No KT J Mol Graph Model; 2018 Jan; 79():46-58. PubMed ID: 29136547 [TBL] [Abstract][Full Text] [Related]
5. Exploring the chemical space of protein-protein interaction inhibitors through machine learning. Choi J; Yun JS; Song H; Kim NH; Kim HS; Yook JI Sci Rep; 2021 Jun; 11(1):13369. PubMed ID: 34183730 [TBL] [Abstract][Full Text] [Related]
6. Benchmark Study Based on 2P2I Wang Z; Kang Y; Li D; Sun H; Dong X; Yao X; Xu L; Chang S; Li Y; Hou T J Phys Chem B; 2018 Mar; 122(9):2544-2555. PubMed ID: 29420886 [TBL] [Abstract][Full Text] [Related]
9. Identification of Bioactive Scaffolds Based on QSAR Models. Nakagawa T; Miyao T; Funatsu K Mol Inform; 2018 Jan; 37(1-2):. PubMed ID: 29135084 [TBL] [Abstract][Full Text] [Related]
10. Ligand specificity, privileged substructures and protein druggability from fragment-based screening. Barelier S; Krimm I Curr Opin Chem Biol; 2011 Aug; 15(4):469-74. PubMed ID: 21411360 [TBL] [Abstract][Full Text] [Related]
11. Machine Learning Distinguishes with High Accuracy between Pan-Assay Interference Compounds That Are Promiscuous or Represent Dark Chemical Matter. Jasial S; Gilberg E; Blaschke T; Bajorath J J Med Chem; 2018 Nov; 61(22):10255-10264. PubMed ID: 30422657 [TBL] [Abstract][Full Text] [Related]
12. Are target-family-privileged substructures truly privileged? Schnur DM; Hermsmeier MA; Tebben AJ J Med Chem; 2006 Mar; 49(6):2000-9. PubMed ID: 16539387 [TBL] [Abstract][Full Text] [Related]
13. Phantom PAINS: Problems with the Utility of Alerts for Pan-Assay INterference CompoundS. Capuzzi SJ; Muratov EN; Tropsha A J Chem Inf Model; 2017 Mar; 57(3):417-427. PubMed ID: 28165734 [TBL] [Abstract][Full Text] [Related]
14. Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Guo W; Wisniewski JA; Ji H Bioorg Med Chem Lett; 2014 Jun; 24(11):2546-54. PubMed ID: 24751445 [TBL] [Abstract][Full Text] [Related]
15. Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening. Magee TV Bioorg Med Chem Lett; 2015 Jun; 25(12):2461-8. PubMed ID: 25971770 [TBL] [Abstract][Full Text] [Related]
16. Small molecules, big targets: drug discovery faces the protein-protein interaction challenge. Scott DE; Bayly AR; Abell C; Skidmore J Nat Rev Drug Discov; 2016 Aug; 15(8):533-50. PubMed ID: 27050677 [TBL] [Abstract][Full Text] [Related]
17. Privileged structures: efficient chemical "navigators" toward unexplored biologically relevant chemical spaces. Kim J; Kim H; Park SB J Am Chem Soc; 2014 Oct; 136(42):14629-38. PubMed ID: 25310802 [TBL] [Abstract][Full Text] [Related]
18. State-of-the-art strategies for targeting protein-protein interactions by small-molecule inhibitors. Sheng C; Dong G; Miao Z; Zhang W; Wang W Chem Soc Rev; 2015 Nov; 44(22):8238-59. PubMed ID: 26248294 [TBL] [Abstract][Full Text] [Related]
19. Computational derivation of structural alerts from large toxicology data sets. Ahlberg E; Carlsson L; Boyer S J Chem Inf Model; 2014 Oct; 54(10):2945-52. PubMed ID: 25275755 [TBL] [Abstract][Full Text] [Related]
20. Diversity-oriented synthetic strategy for developing a chemical modulator of protein-protein interaction. Kim J; Jung J; Koo J; Cho W; Lee WS; Kim C; Park W; Park SB Nat Commun; 2016 Oct; 7():13196. PubMed ID: 27774980 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]